Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
_256_384.png)
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Study achieves primary endpoint of radiographic progression-free survival
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Transformation to pure-play Innovative Medicines company nears completion
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Orion to receive an upfront payment of USD 290 million
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Subscribe To Our Newsletter & Stay Updated
